2-Isopropylmercapto-N-methyl-anilin | 91330-05-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-Isopropylmercapto-N-methyl-anilin
• 英文别名: N-methyl-2-propan-2-ylsulfanylaniline
• CAS: 91330-05-1
• 化学式: C₁₀H₁₅NS
• 分子量: 181.302
• InChiKey: WHXUXRSZZINPEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS
  申请人：Suzhou Zelgen Biopharmaceuticals Co. Ltd.

  公开号：EP2990405A1

  公开（公告）日：2016-03-02

  The present invention related to deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds. In particular, disclosed are the deuterated diaminopyrimidine compounds shown as formula (I), and the pharmaceutical compositions comprising such compounds or crystal form, pharmaceutically acceptable salts, hydrates or solvates thereof. The compounds of the present invention can be used for treating and/or preventing protein kinase-associated diseases, such as cell proliferative disease, cancer, immune disease and the like.

  本发明涉及氘代二胺嘧啶化合物和包含此类化合物的药物组合物。特别是公开了式(I)所示的氘代二胺嘧啶化合物，以及包含此类化合物或其晶体、药学上可接受的盐、水合物或溶液的药物组合物。本发明的化合物可用于治疗和/或预防蛋白激酶相关疾病，如细胞增殖性疾病、癌症、免疫疾病等。
• Compounds for the modulation of myc activity
  申请人：Syros Pharmaceuticals, Inc.

  公开号：US10787444B2

  公开（公告）日：2020-09-29

  The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.

  本发明提供了式(I)和式(II)的新型化合物及其药学上可接受的盐、溶液剂、水合物、同系物、立体异构体、同位素标记的衍生物及其组合物。还提供了涉及这些化合物或组合物的方法和试剂盒，用于治疗或预防增殖性疾病，如癌症（如乳腺癌、前列腺癌、淋巴瘤、肺癌、胰腺癌、卵巢癌、神经母细胞瘤或结肠直肠癌）、良性肿瘤、血管生成、炎症性疾病、纤维化（如多囊肾）、自身炎症性疾病和自身免疫性疾病。
• [EN] DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS<br/>[FR] COMPOSÉS DIAMINOPYRIMIDINES DEUTÉRIÉS, ET COMPOSITIONS PHARMACEUTIQUES COMPRENANT CES COMPOSÉS
  申请人：SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD

  公开号：WO2014173291A1

  公开（公告）日：2014-10-30

  本发明涉及氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物。具体地，本发明公开了式（I）所示的氘代的二氨基嘧啶化合物以及含有该化合物、或其晶型、药学上可接受的盐、水合物或溶剂合物的药物组合物。本发明的化合物可用于治疗和/或预防蛋白激酶相关性疾病，例如细胞增殖性疾病、癌症、免疫性疾病等。
• COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY
  申请人：Roberts Christopher

  公开号：US20180162851A1

  公开（公告）日：2018-06-14

  The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.